GLP-1 receptor agonists were unequivocally associated with heart rate increase of varying magnitude, which, however, did not increase the risk of major adverse cardiac events in patients with T2D and high cardiovascular risk17,18. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.